Topiramate add-on for drug-resistant partial epilepsy

Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures

“…The lack of efficacy for topiramate observed in this study differs from results obtained in adults and children older than 2 years with refractory POS, [14][15][16][17][18] suggesting fundamental differences in refractory POS experienced by infants. Topiramate, at dosages ranging from 1 to 24 mg/kg/d, was effective in controlling multiple seizure types and was well tolerated in pediatric patients (aged 1-18 years) with refractory epilepsy in an open-label study.…”

Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures

“…The lack of efficacy for topiramate observed in this study differs from results obtained in adults and children older than 2 years with refractory POS, [14][15][16][17][18] suggesting fundamental differences in refractory POS experienced by infants. Topiramate, at dosages ranging from 1 to 24 mg/kg/d, was effective in controlling multiple seizure types and was well tolerated in pediatric patients (aged 1-18 years) with refractory epilepsy in an open-label study.…”

Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy

“…The spectrum of adverse events associated with TPM in our study, corresponds, to a high degree, to the results of other studies in adults and children with TPM both as add‐on‐therapy and as monotherapy (Kellett et al 1999, Sziklas et al 1999, Thompson et al 1999, Abou‐Khalill et al 2000, Arroyo et al 2000, Biton et al 2001, Contin et al 2002, Guberman et al 2002, Jette et al 2002, Christensen et al 2003, Dlugos et al 2003, Dodson et al 2003, Gilliam et al 2003, Krakow et al 2003, Mikaeloff et al 2003, Reith et al 2003); this is especially true for the comparison with the results of Reife et al (1995b, 2000) in 5, double‐blind, placebo‐controlled parallel group studies. Their results were the basis of our list of questions regarding adverse events.…”

Effect of Topiramate on Glucocorticoid Receptor Mediated Action

“…In laboratory studies, TPM blocked the effects of kainite-induced excitatory conductance in cultured rat hippocampal neurons (Gibbs et al, 2000), and reduced the effects of hippocampal neuronal damage in gerbils caused by ischemia (Lee et al, 2000). These and other preclinical findings have provided a putative mechanism for the effects of TPM as an anticonvulsant (Jahromi et al, 2000;Shank et al, 2000), and are consistent with some clinical reports of the antiepileptic effects and mood-stabilizing effects of this compound (Chengappa et al, 1999;Jette et al, 2002;Privitera et al, 2003).…”

Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures

“…The lack of efficacy for topiramate observed in this study differs from results obtained in adults and children older than 2 years with refractory POS, [14][15][16][17][18] suggesting fundamental differences in refractory POS experienced by infants. Topiramate, at dosages ranging from 1 to 24 mg/kg/d, was effective in controlling multiple seizure types and was well tolerated in pediatric patients (aged 1-18 years) with refractory epilepsy in an open-label study.…”

Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy

“…The spectrum of adverse events associated with TPM in our study, corresponds, to a high degree, to the results of other studies in adults and children with TPM both as add‐on‐therapy and as monotherapy (Kellett et al 1999, Sziklas et al 1999, Thompson et al 1999, Abou‐Khalill et al 2000, Arroyo et al 2000, Biton et al 2001, Contin et al 2002, Guberman et al 2002, Jette et al 2002, Christensen et al 2003, Dlugos et al 2003, Dodson et al 2003, Gilliam et al 2003, Krakow et al 2003, Mikaeloff et al 2003, Reith et al 2003); this is especially true for the comparison with the results of Reife et al (1995b, 2000) in 5, double‐blind, placebo‐controlled parallel group studies. Their results were the basis of our list of questions regarding adverse events.…”

Effect of Topiramate on Glucocorticoid Receptor Mediated Action

“…In laboratory studies, TPM blocked the effects of kainite-induced excitatory conductance in cultured rat hippocampal neurons (Gibbs et al, 2000), and reduced the effects of hippocampal neuronal damage in gerbils caused by ischemia (Lee et al, 2000). These and other preclinical findings have provided a putative mechanism for the effects of TPM as an anticonvulsant (Jahromi et al, 2000;Shank et al, 2000), and are consistent with some clinical reports of the antiepileptic effects and mood-stabilizing effects of this compound (Chengappa et al, 1999;Jette et al, 2002;Privitera et al, 2003).…”

Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures

“…The lack of efficacy for topiramate observed in this study differs from results obtained in adults and children older than 2 years with refractory POS, [14][15][16][17][18] suggesting fundamental differences in refractory POS experienced by infants. Topiramate, at dosages ranging from 1 to 24 mg/kg/d, was effective in controlling multiple seizure types and was well tolerated in pediatric patients (aged 1-18 years) with refractory epilepsy in an open-label study.…”

Topiramate: a prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy

“…The spectrum of adverse events associated with TPM in our study, corresponds, to a high degree, to the results of other studies in adults and children with TPM both as add‐on‐therapy and as monotherapy (Kellett et al 1999, Sziklas et al 1999, Thompson et al 1999, Abou‐Khalill et al 2000, Arroyo et al 2000, Biton et al 2001, Contin et al 2002, Guberman et al 2002, Jette et al 2002, Christensen et al 2003, Dlugos et al 2003, Dodson et al 2003, Gilliam et al 2003, Krakow et al 2003, Mikaeloff et al 2003, Reith et al 2003); this is especially true for the comparison with the results of Reife et al (1995b, 2000) in 5, double‐blind, placebo‐controlled parallel group studies. Their results were the basis of our list of questions regarding adverse events.…”

Effect of Topiramate on Glucocorticoid Receptor Mediated Action

“…In laboratory studies, TPM blocked the effects of kainite-induced excitatory conductance in cultured rat hippocampal neurons (Gibbs et al, 2000), and reduced the effects of hippocampal neuronal damage in gerbils caused by ischemia (Lee et al, 2000). These and other preclinical findings have provided a putative mechanism for the effects of TPM as an anticonvulsant (Jahromi et al, 2000;Shank et al, 2000), and are consistent with some clinical reports of the antiepileptic effects and mood-stabilizing effects of this compound (Chengappa et al, 1999;Jette et al, 2002;Privitera et al, 2003).…”